Amundi
PMVP icon

Amundi’s PMV Pharmaceuticals PMVP Stock Holding History

Amundi’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,182
Closed -$38.9K – 2183
2024
Q3 		$38.9K Buy
+26,182
New +$40.5K ﹤0.01% 1865
2024
Q2 		– Sell
-26,182
Closed -$42.4K – 2022
2024
Q1 		$42.4K Hold
26,182
– – ﹤0.01% 1857
2023
Q4 		$68.1K Buy
+26,182
New +$69.3K ﹤0.01% 1846

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Amundi's PMVP Position: Q4 2024 in Review

Amundi sold out of PMV Pharmaceuticals (PMVP) in Q4 2024, closing a stake of 26,182 shares — an estimated $38.9K sold.

Amundi first reported a position in PMVP in Q4 2023 and held it in 3 quarters. The position peaked at $68.1K in Q4 2023. 70 funds tracked by Wall St. Rank hold PMVP as of Q4 2024.

  • Amundi reported no remaining PMV Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Amundi sold 26,182 PMV Pharmaceuticals shares in Q4 2024, an estimated $38.9K.
  • Amundi first reported a position in PMV Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Amundi's PMV Pharmaceuticals position peaked at $68.1K in Q4 2023.
  • 70 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2024.

Based on Amundi's 13F filing for Q4 2024, filed 7 Feb 2025.